Heron Therapeutics ( (HRTX) ) has issued an announcement.
On May 6, 2025, Heron Therapeutics announced a settlement agreement with Mylan Pharmaceuticals to resolve patent litigations concerning CINVANTI® and APONVIE® injectable emulsions in the U.S. District Court for the District of Delaware. As part of the settlement, Heron granted Mylan a license to market generic versions of these products in the U.S. starting June 1, 2032, or earlier under certain conditions. The litigations were initiated by Heron in response to Mylan’s applications for FDA approval of generic versions before the expiration of Heron’s patents in 2035. This agreement will lead to the dismissal of the pending litigations, potentially impacting Heron’s market exclusivity and future revenue streams.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics shows potential with its revenue growth and strategic appointments. However, significant financial challenges, including profitability issues and high leverage, weigh heavily on its stock score. While recent profitability and operational improvements are notable, ongoing risks such as cash flow management and market competition pose substantial concerns.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving patient care through the development and commercialization of therapeutic innovations. The company specializes in products that enhance the standard-of-care for acute care and oncology patients.
Average Trading Volume: 1,794,306
Technical Sentiment Signal: Sell
Current Market Cap: $351.9M
For an in-depth examination of HRTX stock, go to TipRanks’ Stock Analysis page.